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Abstract
Objectives. The aim of the research was to assess the cardiovascular risk in patients with systemic lupus erythematosus (SLE). 
Materials and Methods. Cross-sectional study, including 96 patients with Systemic Lupus Erythematosus (The Systemic Lupus Collaborating Clinics 
classification criteria, 2012), was conducted at the Department of Internal Medicine, Institute of Cardiology, Chișinău, Republic of Moldova, between 
2017-2019 years. We calculated and compared the 10-year cardiovascular risk by Systemic Coronary Risk Evaluation versus Systemic Lupus Erythematosus 
cardiovascular risk equation. 
Results. A total number of 96 patients were included in the study, with female gender predominance (92 patients, 96%) and mean age, at the moment of 
the study, of 43.2±12.1 years. The Systemic Lupus Erythematosus duration was 89,9±44,1 months. The disease activity by Systemic Lupus Erythematosus 
Disease Activity Index was 8.08±7,1 points. Traditional cardiovascular risk factors were hypertension (50%), age (16.6%) and hypercholesterolemia 
(12.5%). Non-traditional risk factors were high disease activity (33.3%), antiphospholipidic syndrome (33.3%) and renal lupus (20.8%). The mean 10-year 
risk provided by Systemic Coronary Risk Evaluation was 7.8±9.0 points. Overall, 12.5% participants were deemed high risk, most of the subjects having 
moderate 45.8% or low 41.7% cardiovascular risk. According to Systemic Lupus Erythematosus Cardiovascular Risk Equation, we have established that 
29.1% of patients had high cardiovascular risk, compared to only 12.5% by Systemic Coronary Risk Evaluation (p<0.05). 
Conclusion. Patients with Systemic Lupus Erythematosus have a high cardiovascular risk, by combining traditional and non-traditional risk factors (disease 
activity, lupus nephritis and antiphospholipid syndrome). For clinical use, the specific tool for stratifying cardiovascular risk in Systemic Lupus Erythematosus 
is recommended.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic and 
multisystemic disorder, linked to loss of immune tolerance to 
self-antigens and the production of a variety of autoantibodies, 
predominantly affecting women of childbearing age. Out of 10-
20% of all SLE cases occur, approximately, in the first two decades 
of life. Its course is characterized by periods of exacerbation and 
remission with breakouts that are difficult to control. The most 
common cause of death in SLE patients, that are affected for 
more than 5 years, is cardiovascular disease (CVD) [1].
Coronary artery disease (CAD) is one of the cardiovascular 
manifestations observed in young SLE patients. The clinical 
manifestations of CAD in SLE can result from several 
pathophysiologic mechanisms, including atherosclerosis, 
arteritis, thrombosis, embolization, spasm, and abnormal 
coronary flow [2, 3, 4].
The striking clinical characteristic of most patients with SLE, 
who have a Myocardial Infarction (MI), is their young age. This 
demographic characteristic suggests that patients with SLE are 
at increased risk of MI and that reports of MI in patients with 
SLE do not simply represent chance occurrences. Fatal MI has 
been reported to be 3 times higher in patients with SLE than in 
age – and gender – matched control subjects [4, 6]. Recent case-
control series have confirmed that the risk of MI in patients with 
SLE is increased between 9 and 50 fold over that in the general 
population [7]. It has been increasingly recognized that patients 
with SLE have a high cardiovascular mortality.
The impact of coronary heart disease (CHD) on morbidity 
and mortality in patients with established SLE has assumed 
increasing importance in their long-term management. SLE 
is a chronic inflammation of organism and inflammation is a 
prominent feature of atherosclerotic lesions [7]. To prove CVD 
features in SLE we observed the prevalence of clinically manifest 
ischemic heart disease has ranged between 8% and 16% in 
various studies [8-10].
Clinical epidemiological observations strongly suggest 
that, together with classical conventional risk factors, other 
mechanisms (non-conventional/disease-specific factors) 
promote accelerated atherosclerosis in inflammatory diseases 
like SLE [6-8]. SLE is now considered to be an independent 
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risk factor for the development of atherosclerosis. Viewing 
atherosclerosis as an inflammatory disease, this association 
becomes stronger and better understood.
Based on the above, we aimed to conduct a cross-sectional 
study, which would allow characterizing the cardiovascular risk 
factors in patients with SLE.
Material and methods 
The objective of the study was to assess the cardiovascular 
risk in patients with systemic lupus erythematosus. The study 
was conducted at the Department of Internal Medicine, 
Institute of Cardiology, Chișinău, Republic of Moldova, during 
2017-2019 years.
Clinical and socio-demographic data were collected, 
according to The Systemic Lupus Collaborating Clinics 
classification criteria SLICC 2012, Systemic Lupus 
Erythematosus Disease Activity Index SLEDAI-2k, traditional 
and non-traditional cardiovascular risk factors were assessed. 
In the end of the study, we have appreciated the 10 year 
cardiovascular risk by Systemic Coronary Risk Evaluation 
SCORE versus SLE cardiovascular risk equation. 
The research was approved by the Ethics Committee of State 
University of Medicine and Pharmacy "Nicolae Testemițanu" 
(session no. 78 of 08.06.2017). The study was conducted 
according to the ethical standards in the Helsinki Declaration of 
1975, as revised in 2000 (5), as well as the national law.
The necessary number of subjects was calculated by applying 
the formula for cross-sectional studies: n = P(1-P)(Zα/d)2, 
where: P = 0.000026 (incidence of SLE), Zα = 1.96, d = 0.001. 
The statistical analysis was performed in Microsoft Excel 
2010 and MedCalc statistical software, version 12.7.0. The results 
were presented as mean values ± standard deviation for normal 
distribution data and medians with range for skewed data. The 
statistical difference was calculated using t-Student criteria; the 
95% confidence intervals were presented. The correlations were 
calculated by Pearson coefficient. 
Results 
A total of 96 patients were eligible according to the inclusion 
criteria and were enrolled in the study. The table 1 illustrates the 
general characteristic of the study group.
Table 1 
General characteristics of the study group (n = 96)
Parameters Result
Race: European 100%
Gender
• Female, %
• Male,%
96
4
Residence
• Rural, %
• Urban, %
58
42
Mean age at the time of the study, years (±SD) 43,2±12,1
(range 24-67)
Mean age at the disease onset, years (±SD) 31,2±13,8
(range14-56)
Mean disease duration, months (±SD) 89,7±45,5
(range 0,1-207)
Mean number of SLICC,2012 classification criteria 6,0±1,66
(range 4-10)
Figure 1. Clinical manifestation of SLE in the study group (n=96).
We have studied the clinical profile of our patients by 
applying SLICC, 2012 classification criteria, which includes 
clinical and immunological manifestations.
 The most common clinical manifestations were acute/
subacute cutaneous lupus and joint involvement, in 95.83% 
and 94.79% cases, respectively. Also, one of the frequent 
manifestations of the disease was serous involvement by 
pericarditis or pleuritis, in 37.50% of the cases. The least 
common findings were neurologic involvement and haemolytic 
anaemia, in only 7.29% and 8.33%.
The immunological changes are of a great importance in 
patients with SLE and are included in the SLICC criteria. So, we 
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have collected information about the following immunologic 
markers: antinuclear antibody (ANA), anti-double stranded 
DNA antibodies, complement level – C3 and C4, anti-Smith 
antibodies, direct Coombs test and antiphospholipid Ab 
(anti-Cl ab, lupus anticoagulant and anti-beta2 glicoprotein 1 
antibodies. In our patients, 91.66% had positive ANA, 87.50% 
positive anti-double stranded DNA antibodies. Also, 33.33% 
patients had antiphospholipid Ab, which is considered to be a 
non-traditional cardiovascular risk factor.
The next step was the assessment of the disease activity by 
SLEDAI, the value was 8.08±7.1 points, with variations from 
0 to 20 points. We have classified SLEDAI disease activity 
according to the degrees of activity. As per expert consensus, 
SLE activity can be divided into 4 degrees:  mild (less than 5 
points), moderate (6-10 points) and severe activity (11-19 
points) and very severe (more or equal to 20 points).
Figure 2. The classification of SLEDAI according to the of lupus activity (n=96).
According to the figure 2, most of the patients had mild or 
moderate disease activity, with a SLEDAI score up to 10 points 
(66.66%). Only 8.33% of patients had a very active disease, with 
a SLEDAI score of 20 points. 
According to the study design, we aimed to investigate 
cardiovascular risk factors in patients with SLE, including 
traditional and non-traditional risk factors. As traditional risk 
factors, we can mention: the age (men >45 years, women >55 
years), sex (male), current smocking, diabetes mellitus, systolic 
hypertension, and serum cholesterol levels (total cholesterol > 
160mg/dl and high density lipoproteins HDL <40mg/dl).
Regarding the results from our study cohort, traditional risk 
factors were assessed.
Table 2
Conventional cardiovascular risk factors
Parameter Relative value, %
Sex (male) 4.1
Age 9men >45 years, women >55 years) 16.6
Current smoker 8.3
Diabetes mellitus 3.12
Hypertension 50,0
Total cholesterol 12.5
Low HDL 4.1
Concerning cardiovascular risk score in our patients, 
we have applied the SCORE chart for the calculation. The 
stratification of the cardiovascular risk in our patients is shown 
in the following figure.
Figure 3. SCORE stratification in the study population (n=96)
The mean 10-year risk provided by SCORE was 7.8±9.0. 
Overall, 12.5% participants were deemed high risk, most of the 
subjects having moderate 45.8% or low 41.7% cardiovascular 
risk.
Concerning non-traditional CV risk factors, the data from 
the literature cites several factors that have been proved to have 
a negative impact on cardiovascular outcomes in SLE patients. 
Among those, several quantifiable factors were cited:
- Renal involvement
- Inflammatory syndrome and/or SLE activity
- Presence of antiphospholipid (APL) syndrome
Renal involvement, included as well in SLICC, 2012 
classification criteria, was established in 20.83% patients, which 
had increased level of creatinine and/or proteinuria. Concerning 
SLE activity, it was calculated by SLEDAI was found to be high 
and very high in 33.3% patients. Also, 8 (33.3%) of patients were 
found to have positive antiphospholipid antibodies, but only 3 
patients had positive lupus anticoagulant.
After calculating Systemic Lupus Erythematosus 
Cardiovascular Risk Equation in our patients, we have 
established that 29.1% of patients had high cardiovascular risk, 
compared to only 12.5% by SCORE (p<0.05). Consequently, 
16 (16.6%) patients were found to be high risk by Systemic 
Lupus Erythematosus Cardiovascular Risk Equation and low or 
moderate risk by SCORE. 
We were interested to study the cases of two patients with 
different cardiovascular risk scores according to the both 
applied clinical tools.
Clinical case N1
Patient B.E., 39 years old woman, was hospitalized at the 
Institute of Cardiology by emergency.
At presentation, the patient complained of: dizziness and 
paraesthesia in the right upper and lower extremities and 
arthralgia.
Medical history: the patient was diagnosed with SLE 7 
years ago, at the age of 32 years. The disease started with joint 
involvement (arthritis, arthralgia), fever, fatigue and skin 
eruptions. The immunological markers at the time of diagnosis: 
positive antinuclear antibodies ANA, high anti-DNAds Ab and 
positive Lupus Anticoagulant (LA). The patient was treated 
according to the protocol with high doses of corticosteroids and 
aspirin. 
The evolution of the disease was marked by a relapsing 
course, with mild and moderate flares each year, manifested 
mainly by joint involvement.
Treatment regimen at admission: Methylprednisolone 8mg/
day, Aspirin 75mg/day, Calcium D3 500mg/2 times a day. 
Pathological antecedents: no antecedents of Arterial 
Hypertension, Diabetes Mellitus or dyslipidaemia.
Hereditary anamnesis: no particularities.
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Bad habits: none.
Allergies: none.
Physical examination: grave general state. The inspection 
of the skin revealed no cutaneous eruptions. The lymph nodes 
were not enlarged. The thyroid gland – not enlarged. The 
ophthalmologic and neurologic exam was within normal limits. 
The auscultation of the chest – vesicular murmur. The heart 
beats were regular, heart rate 86 beats/minute, blood pressure 
136/82 mm/Hg. The abdomen was smooth, non-tender, the 
liver and the spleen were not palpated. The micturitions were 
regular, not painful, Giordano sign – negative. Joint count: 
swollen joints – 2, tender joints – 5. Neurologic examination 
revealed hypoesthesia and of upper and lower right extremities, 
muscular force was 5/5 on the left side and 3/5 on the right side.
Laboratory tests results: Hemoglobin 116 g/dl, Leucocytes – 
8,6x109/l, Thrombocytes 236x109/l; Erythrocytes sedimentation 
rate 25mm/h. Blood biochemistry: urea – 8.6 mg/dl, creatinine 
– 87 mmol/l, estimated creatinine clearance - 66 mL/min, total 
cholesterol – 4.6 mh/dl, high-density lipoproteins cholesterol – 
1,3 mg/dl. Urine analysis – no micoalbuminuria, erythrocytes 
0, leucocytes 2. Immunological testing: antinuclear antibodies 
ANA – 1:320, Anti-DNAds Ab – 86 U/ml (N<15 U/ml), low C3 
and C4, positive lupus anticoagulant.
Electrocardiogram – normal sinusal rhythm, 72 beats/
minute
Ecocardiography – no pericardial effusion, left ventricle 
ejection fraction 66%, no valve regurgitations
Chest radiography – normal result
Systemic Lupus Erythematosus specific assessment:
• SLEDAI – 8 points (arthritis 4, low complement 2, anti-
DNAds Ab 2)
• SLICC/ACR Damage Index – 0 point 
• SCORE risk score – low (0.2%)
• Systemic Lupus Erythematosus Cardiovascular Risk Equa-
tion – 8 points (by presence of lupus anticoagulant, SLEDAI > 
2p and low complement level) – estimated 10 year risk is 8.9%.
Taking into account anamnesis, physical examination and 
laboratory results a brain CT was ordered, that confirmed an 
thromboembolic stroke. 
Diagnosis: Systemic lupus erythematosus, SLEDAI 8 
points, SLICC/ACR DI 0 point. Secondary antiphospholipidic 
syndrome complicated with embolic stroke.
In conclusion, we have presented a case of a young SLE 
patient, which was admitted to the hospital embolic stroke. The 
use of SCORE showed 0.2% change of cardiovascular events; 
meantime, the use of a more specific tool for SLE patients - 
Systemic Lupus Erythematosus Cardiovascular Risk Equation 
- estimated a 10 year risk of 8.9%.
Clinical case N2
Patient T.C., 33 years old woman, was admitted in the 
intensive care unit with the following complaints: dyspnoea at 
rest, digital ulcers, oral ulcers. 
Medical history: The patient was diagnosed with SLE 8 
months ago. The disease started with fatigue, fever and arthritis. 
The immunological markers at the time of diagnosis: positive 
ANA and high anti-DNAds Ab, high anti cardiolipin Ab titers. 
The patient was prescribed high dose prednisolone and 
aspirin. It is to note that the patient has decreased by herself 
her prednisolone dosage, at the time of hospitalization – 
Methylprednisolone 4 mg/day and no aspirin intake. 
Pathological antecedents: 1 miscarriage at the age of 27 
years.
Hereditary anamnesis: no particularities.
Bad habits: current smocking.
Allergies: none.
Physical examination: grave general estate. Acrocyanosis. 
The inspection revealed digital ulcers. The lymph nodes were not 
enlarged. The thyroid gland – not enlarged. The ophthalmologic 
and neurologic exam was within normal limits. Respiratory rate 
– 23/minute. The auscultation of the chest – diffuse crepitations. 
SaO2 at rest – 72%. The heart beats were regular, heart rate 102 
beats/minute, blood pressure 123/85 mm/Hg. The abdomen 
was smooth, non-tender, the liver and the spleen were not 
palpated. The micturitions were regular, non-painful, Giordano 
sign – negative. Joint count: swollen joints – 0, tender joints – 2.
Figure 4. Digital ulcers (lupus vasculitis)
Laboratory tests results: Hemoglobin – 106 g/dl, Leucocytes 
– 4,1x109/l, Thrombocytes – 166x109/l; Erythrocytes 
sedimentation rate – 34 mm/h. Blood biochemistry: urea – 9,6 
mg/dl, creatinine – 45 umol/l, estimated creatinine clearance – 
79 mL/min, total cholesterol – 3,9 mh/dl, HDL cholesterol – 1,4 
mg/dl. Urine analysis – micoalbuminuria – 2 mg/l, erythrocytes 
– 0, leucocytes – 3. Immunological testing: ANA – 1:640, Anti-
DNAds Ab – 187 U/ml (N<15 U/ml), low C3 and C4, presence 
of positive anti-cardiolipin Ab and anti-beta2GP1 Ab. 
Electrocardiogram – sinusal tachycardia, 102 beats/minute
Echocardiography – no pericardial effusion, ejection 
fraction 56%, pulmonary artery hypertension 56 mm/Hg
Chest radiography – signs of pulmonary thromboembolism
Chest computer tomography – confirmation of pulmonary 
artery thromboembolism
Assessment by clinical tools: 
• SLEDAI – 14 points (vasculitis 8, oral ulcers 2, low comple-
ment 2, anti-DNAds Ab 2)
• SLICC/ACR DI – 1 point (pulmonary hypertension)
• SCORE – low (0.4%)
• Systemic Lupus Erythematosus Cardiovascular Risk 
Equation – 1 points (by presence of LA, SLEDAI >2p and low 
complement level, current smocking and low complement level) 
– estimated 10 year risk is 14.2%.
Taking into account anamnesis, physical examination 
and laboratory results a clinical diagnosis was established: 
Systemic lupus erythematosus, SLEDAI 14 points, SLICC/ACR 
DI 1 point, severe flare with lupus vasculitis. Comorbidities: 
Secondary antiphospholipid syndrome, complicated by 
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pulmonary thromboembolism. 
Discussions
Traditional CVD risk factors included age, Arterial 
Hypertension, Diabetes Mellitus, dyslipidemia, previous 
vascular event defined as previous history of cerebrovascular 
accidents or ischemic heart disease, menopause and smoking [8, 
9, 10]. Among these factors Arterial Hypertension, dyslipidemia 
and hypercholesterolemia have been shown to be more 
prevalent in SLE [10]. Metabolic syndrome (MetS) is considered 
an independent predictor of cardiovascular morbidity and 
mortality that identifies substantial additional cardiovascular 
risk beyond the sum of the individual risk factors. In addition 
to the cardiovascular risk factors that comprise the MetS, there 
is a strong relationship with inflammation. Several studies have 
shown that the prevalence of MetS is increased in SLE [11].
An important finding is that SLE patients have an 
increased risk for cardiovascular events even after adjustment 
for Framingham risk factors ( Arterial Hypertension, 
hypercholesterolemia, Diabetes Mellitus, older age, and 
postmenopausal status) [12], so it is necessary to develop other 
methods to determine the subgroup of SLE patients that are 
at highest risk for CVD disease. However, traditional CV risk 
factors alone cannot explain the excess risk of premature CV 
disease among SLE patients and this suggests that disease-
related factors constitute an equal or even greater risk.
The results of our study showed a prevalence of traditional 
cardiovascular risk factors to be different for smoking and 
Arterial Hypertension published in other SLE studies [13, 
14], where the smocking prevalence is higher, but the data 
for Arterial Hypertension is lower, however, the prevalence of 
diabetes dyslipidaemia was comparable [13, 14, 15]. 
The prevalence of diabetes (4.1%), was similar to the 
general population of females aged 45–54 years. In contrast, 
hypercholesterolemia (>5.5 mmol/L) was significantly less 
prevalent in the SLE sample (12.5% vs 33%; p value<0.01) [13, 
14, 16, 17].
Conclusions
Patients with SLE have a high cardiovascular risk, by 
combining traditional and non-traditional risk factors (disease 
activity, lupus nephritis and antiphospholipidic syndrome). For 
clinical use, the specific tool for stratifying cardiovascular risk 
in SLE is recommended.
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